Generic apixaban is not yet available in the United States. The key patents on Eliquis, the brand-name version, don’t expire until November 21, 2026, and additional FDA exclusivity periods extend into late 2028. That means US patients will likely need to wait until sometime between late 2026 and late 2028 before filling a generic prescription at their pharmacy.
Why Generic Apixaban Isn’t Available Yet
Eliquis is protected by multiple patents covering its use in preventing stroke, treating deep vein thrombosis, preventing blood clots after surgery, and treating venous thromboembolism. All of these patents share the same expiration date: November 21, 2026. Until that date, no generic manufacturer can legally sell apixaban in the US for those uses.
Beyond the patents themselves, the FDA has granted additional exclusivity periods that push the timeline further out. A “new patient population” exclusivity and a “new strength” exclusivity both run until April 17, 2028. On top of that, a pediatric exclusivity extension lasts until October 17, 2028. These exclusivity windows can delay generic entry even after the underlying patents expire, depending on the specific strengths and indications involved.
When US Pharmacies Could Stock It
The most realistic window for generic apixaban reaching US pharmacy shelves falls between late 2026 and late 2028. The exact timing depends on how patent challenges and exclusivity periods play out. At least one company, Accord Healthcare, appears in FDA filings related to generic apixaban, signaling that manufacturers are already preparing to enter the market once they’re legally permitted.
For a generic to launch, the manufacturer needs final FDA approval and must clear all patent and exclusivity hurdles. Several generic drugmakers typically file applications well ahead of patent expiration dates, so multiple generics could arrive relatively quickly once the legal barriers fall. When that happens, competition among manufacturers tends to drive prices down within the first year or two.
How Much Cheaper Generics Could Be
Apixaban is one of the most expensive commonly prescribed blood thinners. Over a patient’s treatment lifetime, drug costs for brand-name apixaban average around $51,923 per patient, far exceeding the costs associated with older alternatives like warfarin ($459) or even other newer blood thinners like dabigatran ($35,187) and rivaroxaban ($38,032).
Economic models project that generic blood thinners in this class will initially cost about 35% less than their brand-name counterparts. That’s a meaningful reduction, though not as dramatic as the 80-90% drops seen with some older generics. As more manufacturers enter the market, the price gap typically widens further. For patients currently paying high out-of-pocket costs for Eliquis, generic availability could save hundreds or even thousands of dollars per year.
What Makes a Generic “the Same” as Eliquis
The FDA requires generic apixaban to prove it delivers the same amount of active drug into the bloodstream as brand-name Eliquis. Specifically, manufacturers must run a single-dose crossover study in healthy adults comparing their generic 5 mg tablet to the brand-name version. The study measures apixaban levels in the blood, and the generic must fall within a tight statistical range (a 90% confidence interval) to be approved.
For the 2.5 mg strength, manufacturers can request a waiver from a separate human study as long as they demonstrate that the formulation is proportionally similar to the 5 mg tablet and passes comparative dissolution testing. This is standard practice for drugs available in multiple strengths and doesn’t indicate any lower standard of quality. Once approved, the FDA rates a generic as therapeutically equivalent, meaning pharmacists can substitute it for the brand name.
Options While You Wait
If you’re paying a lot out of pocket for Eliquis right now, a few options exist. Bristol-Myers Squibb and Pfizer, the companies behind Eliquis, offer a manufacturer copay card that can reduce costs for commercially insured patients. Some Medicare Part D plans have negotiated lower prices through the Inflation Reduction Act’s drug pricing provisions. Patient assistance programs also exist for uninsured or underinsured individuals.
Some patients ask about purchasing generic apixaban from countries where it may already be available. While certain international markets have approved generic versions, importing prescription drugs from abroad is generally not legal in the US and carries risks related to product quality and supply chain integrity. Your pharmacist can help you explore domestic cost-reduction options in the meantime.